58451AST
CHIRALPAK® HSA HPLC Column
5 μm particle size, L × I.D. 15 cm × 4 mm
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
material
stainless steel column
Quality Level
Agency
suitable for USP L79
product line
CHIRALPAK®
packaging
pkg of 1 ea
manufacturer/tradename
CHIRALPAK®
parameter
137 bar pressure (2000 psi)
20-30 °C temperature
40 °C max. temp.
technique(s)
HPLC: suitable
L × I.D.
15 cm × 4 mm
matrix
fully porous particle
matrix active group
human serum albumin phase
particle size
5 μm
operating pH
2-8
separation technique
chiral
Looking for similar products? Visit Product Comparison Guide
General description
CHIRALPAK HSA, which uses human serum albumin as the chiral selector, is highly selective for acidic racemates, preferably weak and strong acids, zwitterionic and non-protolytic (neutral) compounds. Phosphate buffers (normally 0.01-0.1M, pH 5-7) with addition of organic modifiers are used as mobile phases. Enantioselectivity and retention can be regulated by changing the mobile phase composition. However, the primary use of CHIRALPAK HSA is for fast drug/protein binding studies (1). To calculate the % protein binding, measure the retention time of an unretained compound (t0) and the compound of interest (tr) on the CHIRALPAK HSA column. Then use the capacity factor equation:
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)
Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.
(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)
Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.
(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.
Legal Information
CHIRALPAK is a registered trademark of Daicel Corp.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service